Essa Pharma Stock Investor Sentiment

EPIX Stock  USD 1.79  0.02  1.10%   
Slightly above 75% of ESSA Pharma's investor base is looking to short. The analysis of the overall investor sentiment regarding ESSA Pharma suggests that many traders are alarmed. ESSA Pharma's investing sentiment can be driven by a variety of factors including economic data, ESSA Pharma's earnings reports, geopolitical events, and overall market trends.
  

ESSA Pharma Sentiment by Major News Outlets

Investor sentiment, mood or attitude towards ESSA Pharma can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
over two months ago at www.macroaxis.com         
Disposition of 694 shares by Virsik Peter of ESSA Pharma at 6.0 subject to Rule 16b-3
Macroaxis News
over two months ago at www.macroaxis.com         
Disposition of tradable shares by Biotech Growth N V of ESSA Pharma subject to Rule 16b-3
Macroaxis News
over two months ago at www.macroaxis.com         
Acquisition by Virsik Peter of 72782 shares of ESSA Pharma at 3.23 subject to Rule 16b-3
Macroaxis News
over two months ago at news.google.com         
Disposition of 2082 shares by Virsik Peter of ESSA Pharma at 6.03 subject to Rule 16b-3
Google News at Macroaxis
over three months ago at news.google.com         
Analyst maintains stock target on ESSA Pharma, cites positive trial outlook - Investing.com
Google News at Macroaxis
over three months ago at news.google.com         
ESSA Pharma Share Price Crosses Below 50-Day Moving Average of 5.04 - MarketBeat
Google News at Macroaxis
over three months ago at simplywall.st         
Companies Like ESSA Pharma Are In A Position To Invest In Growth
Simply Wall St News at Macroaxis
over three months ago at finance.yahoo.com         
ESSA Pharma Fiscal Q3 Earnings Snapshot
Yahoo News
over three months ago at seekingalpha.com         
ESSA Pharma GAAP EPS of -0.16 beats by 0.09
seekingalpha News
over three months ago at news.google.com         
Trading Report - Stock Traders Daily
Google News at Macroaxis
over three months ago at simplywall.st         
Hedge funds investors have a lot riding on ESSA Pharma Inc. with 40 percent ownership
Simply Wall St News at Macroaxis
over three months ago at news.google.com         
ESSA Pharma Stock Crosses Below Fifty Day Moving Average of 5.67 - Defense World
Google News at Macroaxis
over three months ago at finance.yahoo.com         
ESSA Pharma to Present at the JonesHealthcare Seaside Summit
Yahoo News
over three months ago at news.google.com         
ESSA Pharma Shares Cross Below 50 Day Moving Average of 5.83 - MarketBeat
Google News at Macroaxis
over three months ago at finance.yahoo.com         
With 40 percent stake, ESSA Pharma Inc. seems to have captured hedge funds investors interest
Yahoo News
Far too much social signal, news, headlines, and media speculation about ESSA Pharma that are available to investors today. That information is available publicly through ESSA media outlets and privately through word of mouth or via ESSA internal channels. However, regardless of the origin, that massive amount of ESSA data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of ESSA Pharma news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of ESSA Pharma relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to ESSA Pharma's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive ESSA Pharma alpha.

ESSA Pharma Performance against Dow Jones

 Price Growth (%)  
       Timeline  
1
Disposition of tradable shares by Biotech Growth N V of ESSA Pharma subject to Rule 16b-3
09/05/2024
2
Disposition of 694 shares by Virsik Peter of ESSA Pharma at 6.0 subject to Rule 16b-3
09/09/2024
3
ESSA Pharma Presents Updated Phase 12 Masofaniten Clinical Data at the 2024 ESMO Congress
09/13/2024
4
ESSA Pharma Is In A Good Position To Deliver On Growth Plans
09/16/2024
5
ESSA Pharma Stock Price Passes Above 50-Day Moving Average of 5.52 - MarketBeat
09/27/2024
6
Disposition of 50000 shares by Berger Franklin M of ESSA Pharma at 2.67 subject to Rule 16b-3
10/18/2024
7
ESSA Pharma Insiders Added US709.0k Of Stock To Their Holdings
10/24/2024
8
Disposition of 1879583 shares by Biotech Growth N V of ESSA Pharma at 1.513 subject to Rule 16b-3
11/01/2024
9
ESSA Pharma downgraded by Oppenheimer, Piper Sandler after drug setback in trials
11/04/2024
10
ESSA Pharma Rating Lowered to Market Perform at Oppenheimer
11/07/2024
11
RTW INVESTMENTS, LP Acquires Shares in ESSA Pharma Inc
11/14/2024
12
Oppenheimer Downgrades ESSA Pharma - MSN
11/20/2024

Additional Tools for ESSA Stock Analysis

When running ESSA Pharma's price analysis, check to measure ESSA Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ESSA Pharma is operating at the current time. Most of ESSA Pharma's value examination focuses on studying past and present price action to predict the probability of ESSA Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ESSA Pharma's price. Additionally, you may evaluate how the addition of ESSA Pharma to your portfolios can decrease your overall portfolio volatility.